A Comparison of Bronchodilator Therapy with or without Inhaled Corticosteroid Therapy for Obstructive Airways Disease

New England Journal of Medicine

Volumn 327, Issue 20, 1992, Pages 1413-1419

  Kerstjens, Huib A m ^a   Brand, Paul L p ^a   Hughes, Michael D ^b   Robinson, N Jamie ^b   Postma, Dirkje S ^a   Sluiter, Henk J ^a   Bleecker, Eugene R ^c   Dekhuijzen, P n Richard ^d   de Jong, Petra M ^e   Mengelers, Hein J j ^f   Overbeek, Shelley E ^g   Schoonbrood, Danielle F m e ^h  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; PLACEBO; SALBUTAMOL; TERBUTALINE;

ADULT; ARTICLE; ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG MIXTURE; FEMALE; FORCED EXPIRATORY VOLUME; HOARSENESS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LONG TERM CARE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBSTRUCTIVE AIRWAY DISEASE; PATIENT SELECTION; PRIORITY JOURNAL; TREMOR;

EID: 0026474682     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199211123272003     Document Type: Article

References (45)

1. See NAPS document no. 04985 for two pages of supplementary material. Order from NAPS c/o Microfiche Publications, P.O. Box 3513, Grand Central Station, New York, NY 10163–3513. Remit in advance (in U.S. funds only) $7.75 for photocopies or $4 for microfiche. Outside the U.S. and Canada, add postage of $4.50 ($1.75 for microfiche postage). There is a $15 invoicing charge for all orders filled before payment.
2. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225–44.
3. Sly RM. Mortality from asthma, 1979–1984. J Allergy Clin Immunol 1988; 82: 705–17.
4. Buist AS, Vollmer WM. Reflections on the rise in asthma morbidity and mortality. JAMA 1990; 264: 1719–20.
5. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981–83: case–control study. Lancet 1989; 1: 917–22.
6. Manfreda J, Mao Y, Litven W. Morbidity and mortality from chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140: Suppl: S19–S26.
7. Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 1987; 70: 171–9.
8. Gerritsen J, Koëter GH. Postma DS, Schouten JP, Knol K. Prognosis of asthma from childhood to adulthood. Am Rev Respir Dis 1989; 140: 1325–30.
9. Anthonisen NR. Prognosis in chronic obstructive pulmonary disease: results from multicenter clinical trials. Am Rev Respir Dis 1989; 140: Suppl: S95–S99.
10. Barter CE, Campbell AH. Relationship of constitutional factors and cigarette smoking to decrease in 1-second forced expiratory volume. Am Rev Respir Dis 1976; 113: 305–14.
11. Postma DS, de Vries K, Koëter GH, Sluiter HJ. Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction. Am Rev Respir Dis 1986; 134: 276–80.
12. O'Connor GT, Sparrow D, Weiss ST. The role of allergy and nonspecific airway hyperresponsiveness in the pathogenesis of chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140: 225–52.
13. Kraan J, Koëter GH, v d Mark TW, Sluiter HJ, de Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985; 76: 628–36.
14. Kerrebijn KF, van Essen-Zandvliet EEM, Neijens HJ. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol 1987; 79: 653–9.
15. Barnes PJ. A new approach to the treatment of asthma. N Engl J Med 1989; 321: 1517–27.
16. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990; 142: 832–6.
17. Haahtela T, Jårvinen M, Kava T, et al. Comparison of a β2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388–92.
18. Postma DS, Steenhuis EJ, van der Weele LT, Sluiter HJ. Severe chronic airflow obstruction: can corticosteroids slow down progression? Eur J Respir Dis 1985; 67: 56–64.
19. Postma DS, Peters I, Steenhuis EJ, Sluiter HJ. Moderately severe chronic airflow obstruction: can corticosteroids slow down obstruction? Eur Respir J 1988; 1: 22–6.
20. Weir DC, Gove RI, Robertson AS, Burge PS. Corticosteroid trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone dipropionate. Thorax 1990; 45: 112–7.
21. Engel T, Heinig JH, Madsen O, Hansen M, Weeke ER. A trial of inhaled budesonide on airway responsiveness in smokers with chronic bronchitis. Eur Respir J 1989; 2: 935–9.
22. Auffarth B, Postma DS, de Monchy JGR, van der Mark TW, Boorsma M, Koëter GH. Effects of inhaled budesonide on spirometric values, reversibility, airway responsiveness, and cough threshold in smokers with chronic obstructive lung disease. Thorax 1991; 46: 372–7.
23. Britton J, Hanley SP, Garrett HV, Hadfield JW, Tattersfield AE. Dose related effects of salbutamol and ipratropium bromide on airway calibre and reactivity in subjects with asthma. Thorax 1988; 43: 300–5.
24. Storms WW, Bodman SF, Nathan RA, et al. Use of ipratropium bromide in asthma: results of a multiclinic study. Am J Med 1986; 81: Suppl 5A: 61–6.
25. Tashkin DP, Ashutosh K, Bleecker ER, et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease: a 90-day multi-center study. Am J Med 1986; 81: Suppl 5A: 81–90.
26. van Essen-Zandvliet EEM, Kerrebijn KF. The effect of antiasthma drugs on bronchial hyperresponsiveness. Immunol Allergy Clin North Am 1990; 10: 483–501.
27. Brand PLP, Kerstjens HAM, Postma DS, et al. Long-term multicentre trial in chronic nonspecific lung disease: methodology and baseline assessment in adult patients. Eur Respir J 1992; 5: 21–31.
28. Quanjer PH, ed. Standardized lung function testing. Bull Eur Physiopathol Respir 1983; 19: Suppl 5: 1–95.
29. Miller MR, Pincock achéal. Predicted values: how should we use them? Thorax 1988; 43: 265–7.
30. Pocock SJ. Clinical trials: a practical approach. Chichester, England: John Wiley, 1983:84–7.
31. Cockcroft DW, Killian DN, Mellon JJA, Hargreave FE. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy 1977; 7: 235–43.
32. Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Oxford, England: Blackwell Scientific, 1987.
33. Pride NB, Vermeire P, Allegra L. Diagnostic labels applied to model case histories of chronic airflow obstruction: responses to a questionnaire in 11 North American and Western European countries. Eur Respir J 1989; 2: 702–9.
34. Turner-Warwick M. Some clinical problems in patients with airways obstruction. Chest 1982; 82: Suppl: 3S–7S.
35. Lundgren R, Söderberg M, Hörstedt P, Stenling R. Morphological studies of bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhaled steroids. Eur Respir J 1988; 1: 883–9.
36. Dodge R, Cline MG, Burrows B. Comparisons of asthma, emphysema, and chronic bronchitis diagnoses in a general population sample. Am Rev Respir Dis 1986; 133: 981–6.
37. Tashkin DP, Altose MD, Bleecker ER, et al. The Lung Health Study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. Am Rev Respir Dis 1992; 145: 301–10.
38. Kraan J, Koëter GH, van der Mark TW, et al. Dosage and time effects of inhaled budesonide on bronchial hyperreactivity. Am Rev Respir Dis 1988; 137: 44–8.
39. Weir DC, Robertson AS, Gove RI, Burge PS. Time course of response to oral and inhaled corticosteroids in non-asthmatic chronic airflow obstruction. Thorax 1990; 45: 118–21.
40. Renkema TEJ, Sluiter HJ, Koëter GH, Postma DS. A two-year prospective study on the effect of inhaled and inhaled plus oral corticosteroids in chronic airflow obstruction. Am Rev Respir Dis 1990; 141: Suppl: A504. abstract.
41. Toogood JH. Complications of topical steroid therapy for asthma. Am Rev Respir Dis 1990; 141: Suppl: S89–S96.
42. Higgins RM, Stradling JR, Lane DJ. Should ipratropium bromide be added to beta-agonists in treatment of acute severe asthma? Chest 1988; 94: 718–22.
43. Watson WTA, Becker AB, Simons FER. Comparison of ipratropium solution, fenoterol solution, and their combination administered by nebulizer and face mask to children with acute asthma. J Allergy Clin Immunol 1988; 82: 1012–8.
44. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391–6.
45. van Schayck CP, Dompeling E, van Herwaarden CLA, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ 1991; 303: 1426–31.